Clinical Trial Update: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML [Phase 1]

View source ↗

Summary

Phase 1 study of SL-172154 in acute myeloid leukemia and myelodysplastic syndromes was terminated. Results have been posted on 2026-03-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• SL-172154 (SIRPα-Fc-CD40L)

Snippet

Sponsor: Shattuck Labs, Inc. | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED | Results posted: 2026-03-18